Maxwell Unveils Cutting-Edge Technologies for Advancing Perovskite/HJT Tandem Cells
November 2, 2025 - 19:15
Maxwell has made a significant impact at the 4th Perovskite Technology, Equipment and Materials Forum held in Suzhou. During the event, chairman Jian Zhou took the stage to present the company’s latest advancements in Perovskite/HJT Tandem cell technology. This innovative solution aims to enhance the efficiency and performance of solar energy systems, positioning Maxwell at the forefront of renewable energy development.
The Perovskite/HJT Tandem cell technology combines the advantages of both Perovskite and heterojunction technology, promising higher energy conversion rates and improved stability. Zhou emphasized the importance of collaboration and innovation in driving the solar industry forward, highlighting Maxwell's commitment to research and development in this promising field.
As the demand for sustainable energy solutions continues to grow, Maxwell's advancements in tandem cell technology could play a crucial role in the future of solar energy, making it a key player in the transition towards greener energy sources.
MORE NEWS
September 30, 2026 - 21:59
Micron Technology Tops Lofty Fiscal Q4 Goals, Guides Above ViewsMicron Technology exceeded analyst expectations for its fiscal fourth quarter, delivering results that outperformed even the most optimistic projections on Wall Street. The memory chip maker...
September 30, 2026 - 01:50
Space Force Turns to Laser Systems to Shield Launch Sites from Drone ThreatsThe U.S. Space Force is moving forward with plans to deploy laser technology as part of a broader effort to defend its launch facilities from unauthorized drones. The initiative focuses on...
September 29, 2026 - 04:58
DIU Seeks Investors in Counter-Unmanned Systems TechnologyThe Defense Innovation Unit is looking for private investors to back companies working on counter unmanned systems technology. The effort targets firms building tools to detect, track, and disable...
September 28, 2026 - 02:02
Novo Nordisk (CPSE:NOVO B) Secures Long-Acting Injectable Technology In €1.165 Billion Nanexa Licensing AgreementNovo Nordisk has entered a global licensing agreement with Swedish drug delivery company Nanexa, valued at up to 1.165 billion euros. The deal centers on Nanexa`s PharmaShell technology, a platform...